Akari Therapeutics Plc (AKTX)
0.2677
+0.01
(+4.98%)
USD |
NASDAQ |
Feb 25, 16:00
0.2677
0.00 (0.00%)
After-Hours: 17:57
Akari Therapeutics Research and Development Expense (Quarterly) : 0.2475M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| DBV Technologies SA | 26.82M |
| Cellectis SA | 19.34M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | 2.928M |
| Autolus Therapeutics Plc | 27.72M |